These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
289 related articles for article (PubMed ID: 30557203)
1. Correlation Between Pathologic Complete Response in the Breast and Absence of Axillary Lymph Node Metastases After Neoadjuvant Systemic Therapy. Samiei S; van Nijnatten TJA; de Munck L; Keymeulen KBMI; Simons JM; Kooreman LFS; Siesling S; Lobbes MBI; Smidt ML Ann Surg; 2020 Mar; 271(3):574-580. PubMed ID: 30557203 [TBL] [Abstract][Full Text] [Related]
2. Risk of Positive Sentinel Lymph Node After Neoadjuvant Systemic Therapy in Clinically Node-Negative Breast Cancer: Implications for Postmastectomy Radiation Therapy and Immediate Breast Reconstruction. Samiei S; van Kaathoven BN; Boersma L; Granzier RWY; Siesling S; Engelen SME; de Munck L; van Kuijk SMJ; van der Hulst RRJW; Lobbes MBI; Smidt ML; van Nijnatten TJA Ann Surg Oncol; 2019 Nov; 26(12):3902-3909. PubMed ID: 31359276 [TBL] [Abstract][Full Text] [Related]
3. Neo-adjuvant chemotherapy and axillary de-escalation management for patients with clinically node-negative breast cancer. Shi ZQ; Qiu PF; Liu YB; Cong BB; Zhao T; Chen P; Wang CJ; Zhang ZP; Sun X; Wang YS Breast J; 2019 Nov; 25(6):1154-1159. PubMed ID: 31332886 [TBL] [Abstract][Full Text] [Related]
4. De-escalation of axillary surgery in breast cancer patients treated in the neoadjuvant setting: a Dutch population-based study. Simons JM; Koppert LB; Luiten EJT; van der Pol CC; Samiei S; de Wilt JHW; Siesling S; Smidt ML Breast Cancer Res Treat; 2020 Apr; 180(3):725-733. PubMed ID: 32180074 [TBL] [Abstract][Full Text] [Related]
5. Axillary Nodal Response to Neoadjuvant T-DM1 Combined with Pertuzumab in a Prospective Phase II Multi-Institution Clinical Trial. Weiss A; Jin Q; Waks AG; Yardley D; Spring LM; Wrabel E; Tayob N; Viale G; Krop IE; King TA; Metzger-Filho O J Am Coll Surg; 2024 Mar; 238(3):303-311. PubMed ID: 38047578 [TBL] [Abstract][Full Text] [Related]
6. Axillary response according to neoadjuvant single or dual human epidermal growth factor receptor 2 (HER2) blockade in clinically node-positive, HER2-positive breast cancer. Cha C; Ahn SG; Kim D; Lee J; Park S; Bae SJ; Kim JY; Park HS; Park S; Kim SI; Park BW; Jeong J Int J Cancer; 2021 Oct; 149(8):1585-1592. PubMed ID: 34213778 [TBL] [Abstract][Full Text] [Related]
7. Association of Low Nodal Positivity Rate Among Patients With ERBB2-Positive or Triple-Negative Breast Cancer and Breast Pathologic Complete Response to Neoadjuvant Chemotherapy. Barron AU; Hoskin TL; Day CN; Hwang ES; Kuerer HM; Boughey JC JAMA Surg; 2018 Dec; 153(12):1120-1126. PubMed ID: 30193375 [TBL] [Abstract][Full Text] [Related]
8. Impact of Residual Nodal Disease Burden on Technical Outcomes of Sentinel Lymph Node Biopsy for Node-Positive (cN1) Breast Cancer Patients Treated with Neoadjuvant Chemotherapy. Laws A; Hughes ME; Hu J; Barry WT; Dominici L; Nakhlis F; Barbie T; Duggan M; Weiss A; Rhei E; Carter K; Nimbkar S; Schnitt SJ; King TA Ann Surg Oncol; 2019 Nov; 26(12):3846-3855. PubMed ID: 31222687 [TBL] [Abstract][Full Text] [Related]
9. Association of Tumor Molecular Subtype and Stage with Breast and Axillary Pathologic Complete Response After Neoadjuvant Chemotherapy for Breast Cancer. Myers SP; Ahrendt GM; Lee JS; Steiman JG; Soran A; Johnson RR; McAuliffe PF; Diego EJ Ann Surg Oncol; 2021 Dec; 28(13):8636-8642. PubMed ID: 34142288 [TBL] [Abstract][Full Text] [Related]
10. Can axillary surgery be omitted in patients with breast pathologic complete response after neoadjuvant systemic therapy for breast cancer? A real-world retrospective study in China. Chen R; Li S; Li Y; Zhu Q; Shi X; Xu L; Xu Y; Zhang W; Huang X; Wang J; Zha X J Cancer Res Clin Oncol; 2021 Dec; 147(12):3495-3501. PubMed ID: 34398298 [TBL] [Abstract][Full Text] [Related]
11. Identification of Patients With Documented Pathologic Complete Response in the Breast After Neoadjuvant Chemotherapy for Omission of Axillary Surgery. Tadros AB; Yang WT; Krishnamurthy S; Rauch GM; Smith BD; Valero V; Black DM; Lucci A; Caudle AS; DeSnyder SM; Teshome M; Barcenas CH; Miggins M; Adrada BE; Moseley T; Hwang RF; Hunt KK; Kuerer HM JAMA Surg; 2017 Jul; 152(7):665-670. PubMed ID: 28423171 [TBL] [Abstract][Full Text] [Related]
12. Pathologic Complete Response with Neoadjuvant Doxorubicin and Cyclophosphamide Followed by Paclitaxel with Trastuzumab and Pertuzumab in Patients with HER2-Positive Early Stage Breast Cancer: A Single Center Experience. Singh JC; Mamtani A; Barrio A; Morrow M; Sugarman S; Jones LW; Yu AF; Argolo D; Smyth LM; Modi S; Schweber S; Boafo C; Patil S; Norton L; Baselga J; Hudis CA; Dang C Oncologist; 2017 Feb; 22(2):139-143. PubMed ID: 28167568 [TBL] [Abstract][Full Text] [Related]
13. Prognosis of residual axillary disease after neoadjuvant chemotherapy in clinically node-positive breast cancer patients: isolated tumor cells and micrometastases carry a better prognosis than macrometastases. van Nijnatten TJ; Simons JM; Moossdorff M; de Munck L; Lobbes MB; van der Pol CC; Koppert LB; Luiten EJ; Smidt ML Breast Cancer Res Treat; 2017 May; 163(1):159-166. PubMed ID: 28213782 [TBL] [Abstract][Full Text] [Related]
14. Toward omitting sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with clinically node-negative breast cancer. van der Noordaa MEM; van Duijnhoven FH; Cuijpers FNE; van Werkhoven E; Wiersma TG; Elkhuizen PHM; Winter-Warnars G; Dezentje V; Sonke GS; Groen EJ; Stokkel M; Vrancken Peeters MTFD Br J Surg; 2021 Jun; 108(6):667-674. PubMed ID: 34157085 [TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant chemotherapy and timing of sentinel lymph node biopsy in different molecular subtypes of breast cancer with clinically negative axilla. Bi Z; Liu J; Chen P; Liu Y; Zhao T; Wang C; Zhang Z; Sun X; Qiu P; Cong B; Song X; Wang Y Breast Cancer; 2019 May; 26(3):373-377. PubMed ID: 30666563 [TBL] [Abstract][Full Text] [Related]
16. The Clinical Significance of Breast-only and Node-only Pathologic Complete Response (pCR) After Neoadjuvant Chemotherapy (NACT): A Review of 20,000 Breast Cancer Patients in the National Cancer Data Base (NCDB). Fayanju OM; Ren Y; Thomas SM; Greenup RA; Plichta JK; Rosenberger LH; Tamirisa N; Force J; Boughey JC; Hyslop T; Hwang ES Ann Surg; 2018 Oct; 268(4):591-601. PubMed ID: 30048319 [TBL] [Abstract][Full Text] [Related]
17. Predictive factors of pathologically node-negative disease for HER2 positive and triple-negative breast cancer after neoadjuvant therapy. Shi Z; Wang X; Qiu P; Liu Y; Zhao T; Sun X; Chen P; Wang C; Zhang Z; Cong B; Wang Y Gland Surg; 2021 Jan; 10(1):166-174. PubMed ID: 33633973 [TBL] [Abstract][Full Text] [Related]
18. Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Patients With an Initial Diagnosis of Cytology-Proven Lymph Node-Positive Breast Cancer. Enokido K; Watanabe C; Nakamura S; Ogiya A; Osako T; Akiyama F; Yoshimura A; Iwata H; Ohno S; Kojima Y; Tsugawa K; Motomura K; Hayashi N; Yamauchi H; Sato N Clin Breast Cancer; 2016 Aug; 16(4):299-304. PubMed ID: 26993216 [TBL] [Abstract][Full Text] [Related]
19. Axillary staging in breast cancer patients treated with neoadjuvant chemotherapy in two Dutch phase III studies. Vriens BEPJ; Keymeulen KBMI; Kroep JR; Charehbili A; Peer PG; de Boer M; Aarts MJB; Heuts EM; Tjan-Heijnen VCG; Oncotarget; 2017 Jul; 8(28):46557-46564. PubMed ID: 28177921 [TBL] [Abstract][Full Text] [Related]
20. A model to predict pathologic complete response of axillary lymph nodes to neoadjuvant chemo(immuno)therapy in patients with clinically node-positive breast cancer. Schipper RJ; Moossdorff M; Nelemans PJ; Nieuwenhuijzen GA; de Vries B; Strobbe LJ; Roumen RM; van den Berkmortel F; Tjan-Heijnen VC; Beets-Tan RG; Lobbes MB; Smidt ML Clin Breast Cancer; 2014 Oct; 14(5):315-22. PubMed ID: 24548732 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]